最新ニュース SOL Glb Inv (OTC:SOLCF) 株価情報

SOL Global Investments Corp is a cannabis company with a focus on legal U.S. states. Its strategic investments and partnerships across cultivation, distribution and retail complement the company's R&D program with the University of Miami. It is also involved in Retail, Agriculture, Quick Service Restaurants & Hospitality, Media Technology & Gaming, Energy and New Age Wellness.

SOL GLOBAL INVTS CORP by Sol Global Invts Corp.

SOL Global Investments Corp

Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 14.96% on an annualized basis producing an average annual return of 27.44%. Currently, Iron Mountain has a market capitalization of $29.99 billion. 
Buying $100 In IRM: If an investor had bought $100 of IRM stock 5 years ago, it would be worth $333.50 today based on a price of $102.20 for IRM at the time of writing.
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736518523_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Short Sellers

TMDX

Watching TransMedics Shares, Scorpion Capital Publishes Report On Co. With $0 PT

Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $555 to $460.

Price Target

Analyst Ratings

VRTX

Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1050 to $900.

REGN

Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $900

WIIM

TLRY

Tilray Brands shares are trading lower after the company reported worse-than-expected Q2 revenue results.

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing volatile trading on Friday, briefly regaining the $95,000 market before slumping below $94,000 on a hotter-than-expected j<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">obs market report</a>.
What Happened: The apex cryptocurrency is trading down 2% over the past 24 hours, having visited the $92,000 and $95,000 marks within this timeframe.
Prominent technical analyst DonAlt remains somewhat upbeat about its prospects, despite current volatility.
In his latest technical analysis podcast <a href="https://www.youtube.com/watch?v=x-W-JUZ9jLo">published</a> on Wednesday, DonAlt acknowledged that recent pullbacks have caused concern but stressed that Bitcoin's high timeframe charts remain strong. 
He suggests the reaction to recent dips might be overblown, stating, "Bitcoin still looks quite decent. I think $150,000 would already be significant this cycle."
He also underscored that the maturing market might not deliver the explosive gains seen in previous cycles, urging investors to temper expectations.
Regarding Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), DonAlt pointed to $2,900-$3,000 as a critical support level. 
He doesn't consider Ethereum "cooked" unless it breaks below this range. 
XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), meanwhile, stands out as a top performer. He praised its current chart, saying, "It's just a good-looking chart."
On the topic of FTX payouts, DonAlt suggested that the potential market impact is limited, as many large claim holders have already sold their stakes.
He also emphasized that the crypto market has matured, making sharp corrections less frequent but also reducing the likelihood of dramatic upward moves.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a>
What's Next: Looking ahead, DonAlt predicts the current market cycle is nearing its conclusion, estimating it could wrap up in a few months. 
However, he remains hopeful for an "aggressive last leg" of growth before the cycle ends.
He cited former President Donald Trump's pro-crypto stance as a potential driver for market expansion, noting, "Trump is trying to pump this market, and I think it's still small enough for him to influence."
DonAlt urged caution, emphasizing the importance of managing risk and securing profits, as the market might not replicate previous cycles&#8217; meteoric gains.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42900509/social-media-sentiment-report-shows-only-one-out-of-bitcoin-xrp-dogecoin-is-bullish">Social Media Sentiment Report Shows Only One Out Of Bitcoin, XRP, Dogecoin Is Bullish</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Bitcoin Fights To Regain $94,000: What Does Technical Analysis Say?

Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $190 to $165.

BIIB

Wells Fargo Maintains Equal-Weight on Biogen, Lowers Price Target to $165

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions shares are trading higher after the company reported better-than-expected Q1 financial results.

Roth MKM analyst Mike Niehuser maintains Vizsla Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#AMEX">VZLA</a>) with a Buy and raises the price target from $3 to $3.25.

VZLA

Roth MKM Maintains Buy on Vizsla Silver, Raises Price Target to $3.25

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Equal-Weight and lowers the price target from $335 to $280.

AMGN

Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $280

PCRX

Pacira Biosciences shares are trading higher after the company reported a preliminary year-over-year increase in FY25 revenue.

RVSN

Rail Vision shares are trading higher after the company announced it received a purchase order for its MainLine product from one of the leading Central America freight operators.

Wells Fargo analyst Roger Read maintains Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) with a Overweight and lowers the price target from $87 to $86.

SHEL

Wells Fargo Maintains Overweight on Shell, Lowers Price Target to $86

Roth MKM analyst Scott Fortune reiterates Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy and maintains $70 price target.

Reiteration

Roth MKM Reiterates Buy on Turning Point Brands, Maintains $70 Price Target

Wells Fargo analyst Roger Read maintains Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) with a Overweight and lowers the price target from $186 to $182.

Wells Fargo Maintains Overweight on Marathon Petroleum, Lowers Price Target to $182

Constellation Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) shares are trading lower after the company reported nearly flat third-quarter sales of $2.46 billion, missing the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42909722/constellation-brands-reports-third-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">consensus estimate of $2.53 billion</a>.
Net sales for the Beer segment increased 3% Y/Y to $2.03 billion, and Wine and Spirits declined 14% to $431.4 million. Shipment volume for Beer climbed 1.6%, while Wine and Spirits declined 16.4%.
Gross profit increased 1% to $1.28 billion, and the operating income slid 0.4% to $793 million. The operating margin for the quarter was 32.2%.
Comparable EPS of $3.25 missed the analyst <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of $3.31.</a>
The company generated year-to-date&nbsp;operating cash flow&nbsp;of&nbsp;$2.6 billion, a 9% increase, and&nbsp;free cash flow&nbsp;of&nbsp;$1.6 billion, a 13% growth.
Constellation Brands ended the quarter with $73.7 million in cash and equivalents as of November 30, 2024.
Constellation&#8217;s board declared a quarterly cash dividend of $1.01 per share, payable on February 21, to stockholders of record on February 7.
&#8220;While we continue to face the subdued spend and value seeking behaviors that emerged among legal drinking age consumers in Q2, our Beer Business delivered a sequential increase in our depletions growth rate in Q3,&#8221; said President and CEO Bill Newlands.
Guidance: Constellation Brands lowered FY25 net sales growth outlook to 2% &#8211; 5% <a target="_blank" href="https://ml.globenewswire.com/Resource/Download/709e6f44-1387-465b-848f-c4133db7b367" rel="noreferrer noopener">from 4% – 6%</a>. It also lowered Comparable EPS guidance to $13.40 &#8211; $13.80 from $13.60 – $13.80 against an estimate of $13.71.
Constellation Brands currently sees an operating cash flow of $2.9 billion – $3.1 billion and a <a href="https://www.benzinga.com/calendars/guidance">free cash flow of $1.6 billion – $1.8 billion.</a>
Price Action: STZ shares are trading lower by 4.46% at $209.50 in premarket on the last check Friday.
Photo: T. Schneider via Shutterstock

Earnings

Equities

Large Cap

Guidance

Movers

General

Beer Maker Constellation Brands' Q3 Sales Hit By Subdued Spending; Stock Slides

ZNTL

Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA has granted Fast Track Designation to azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Mercury General Corporation (the "Company," "Mercury" or "We") announced today its preliminary assessment of the impact of the recent wildfires in Southern California.
An extreme wind-driven wildfire event that began on January 7, 2025 has caused widespread damage across parts of Southern California. The wildfires continue to burn, and it will be some time before the Company has an estimate of the total losses caused by this event. Based on information available to date, we expect the losses to exceed our reinsurance retention level of $150 million.
The Company's reinsurance program provides $1,290 million of limits on a per occurrence basis after covered catastrophe losses exceed the Company's retention of $150 million. The Company's reinsurance program also provides coverage for assessments from the California FAIR plan. To the extent that losses are reinsured, the reinsurance program calls for reinstatements of limits to cover future events. If the full $1,290 million limits are used up, then the total reinstatement premium would be $101 million.

Mercury General Anticipates Wildfire Losses In Southern California To Surpass $150M Reinsurance Retention Level; Coverage Available Up To $1.29B With $101M Reinstatement Premium

NEOG

Neogen shares are trading lower after the company issued FY25 revenue guidance below estimates.

Wells Fargo analyst Edward Kelly maintains United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) with a Underweight and raises the price target from $23 to $25.

UNFI

Wells Fargo Maintains Underweight on United Natural Foods, Raises Price Target to $25

SOL Global Investments (TSE:SOL) has released an update. SOL Global Investments has successfully raised CAD 3.6 million through a brokered private ...

SOL Global Completes CAD 3.6M Fundraising Effort

SOL Global Investments (TSE:SOL) has released an update. SOL Global Investments has bolstered its confidence in the Solana ecosystem by investing a...

SOL Global Expands Investment in Solana Tokens

SOL Global acquires an additional $1.5M in solana tokens

SOL Global Investments (TSE:SOL) has released an update. SOL Global Investments has introduced a new staking strategy aimed at boosting returns and...

SOL Global Unveils New Solana Staking Strategy

SOL Global announces Solana investment staking strategy

SOL Global Investments (TSE:SOL) has released an update. SOL Global Investments has expanded its stake in the Solana ecosystem with a $1.5 million ...

SOL Global Boosts Investment in Solana Ecosystem

SOL Global Investments (TSE:SOL) has released an update. SOL Global Investments has made a strategic move by repaying $3.4 million of its debt, red...

SOL Global's Financial Strategy and Debt Reduction

SOL Global announces loan repayment

SOL Global Investments (TSE:SOL) has released an update. SOL Global Investments is shifting its focus solely to the Solana ecosystem by divesting a...

SOL Global Refocuses on Solana with Strategic Shift

SOL Global Investments (TSE:SOL) has released an update. SOL Global Investments has successfully settled its debt totaling $9.6 million by issuing ...

Comments

SOL Glb Inv

ニュース

最新ニュース SOL Glb Inv (OTC:SOLCF) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル